BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kucerova J, Babinska Z, Horska K, Kotolova H. The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015;159:208-14. [DOI: 10.5507/bp.2014.060] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Moreira FP, Jansen K, Mondin TC, Cardoso Tde A, Magalhães PV, Kapczinski F, Frey BN, Oses JP, Souza LD, da Silva RA, Wiener CD. Biological rhythms, metabolic syndrome and current depressive episode in a community sample. Psychoneuroendocrinology 2016;72:34-9. [PMID: 27343724 DOI: 10.1016/j.psyneuen.2016.06.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
2 Fond GB, Lagier JC, Honore S, Lancon C, Korchia T, Sunhary De Verville PL, Llorca PM, Auquier P, Guedj E, Boyer L. Microbiota-Orientated Treatments for Major Depression and Schizophrenia. Nutrients 2020;12:E1024. [PMID: 32276499 DOI: 10.3390/nu12041024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
3 Fond G, Boyer L, Berna F, Godin O, Bulzacka E, Andrianarisoa M, Brunel L, Aouizerate B, Capdevielle D, Chereau I, Coulon N, D'amato T, Dubertret C, Dubreucq J, Faget C, Leignier S, Lançon C, Mallet J, Misdrahi D, Passerieux C, Rey R, Schandrin A, Urbach M, Vidailhet P, Leboyer M, Schürhoff F, Llorca P; the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group. Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort. Br J Psychiatry 2018;213:464-70. [DOI: 10.1192/bjp.2018.87] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
4 Chen VC, Chen CH, Chiu YH, Lin TY, Li FC, Lu ML. Leptin/Adiponectin ratio as a potential biomarker for metabolic syndrome in patients with schizophrenia. Psychoneuroendocrinology 2018;92:34-40. [PMID: 29625373 DOI: 10.1016/j.psyneuen.2018.03.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
5 Horska K, Ruda-Kucerova J, Babinska Z, Karpisek M, Demlova R, Opatrilova R, Suchy P, Kotolova H. Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats. Psychoneuroendocrinology 2016;73:177-85. [PMID: 27504985 DOI: 10.1016/j.psyneuen.2016.07.218] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
6 Vaghef-Mehrabani E, Izadi A, Ebrahimi-Mameghani M. The association of depression with metabolic syndrome parameters and malondialdehyde (MDA) in obese women: A case-control study. Health Promot Perspect 2021;11:492-7. [PMID: 35079595 DOI: 10.34172/hpp.2021.62] [Reference Citation Analysis]
7 Citrome L, Eramo A, Francois C, Duffy R, Legacy SN, Offord SJ, Krasa HB, Johnston SS, Guiraud-Diawara A, Kamat SA, Rohman P. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat 2015;11:3095-104. [PMID: 26719694 DOI: 10.2147/NDT.S91917] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
8 Drazanova E, Kratka L, Vaskovicova N, Skoupy R, Horska K, Babinska Z, Kotolova H, Vrlikova L, Buchtova M, Starcuk Z Jr, Ruda-Kucerova J. Olanzapine exposure diminishes perfusion and decreases volume of sensorimotor cortex in rats. Pharmacol Rep 2019;71:839-47. [PMID: 31394417 DOI: 10.1016/j.pharep.2019.04.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Tizabi Y, Getachew B, Ferguson CL, Csoka AB, Thompson KM, Gomez-paz A, Ruda-kucerova J, Taylor RE. Low Vs. High Alcohol: Central Benefits Vs. Detriments. Neurotox Res 2018;34:860-9. [DOI: 10.1007/s12640-017-9859-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
10 Horska K, Ruda-kucerova J, Karpisek M, Suchy P, Opatrilova R, Kotolova H. Depot risperidone-induced adverse metabolic alterations in female rats. J Psychopharmacol 2017;31:487-99. [DOI: 10.1177/0269881117691466] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
11 Zhou C, Kong D, Zhu X, Wu W, Xue R, Li G, Xu Y, Liu S, Tian H, Zhuo C. Rethinking Schizophrenia and Depression Comorbidity as One Psychiatric Disorder Entity: Evidence From Mouse Model. Front Neurosci 2020;14:115. [PMID: 32218718 DOI: 10.3389/fnins.2020.00115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
12 Lange SMM, Schirmbeck F, Stek ML, Murk Jansen YR, van Rooijen G, de Haan L, Penninx BWJH, Rhebergen D; GROUP investigators. A comparison of depressive symptom profiles between current major depressive disorder and schizophrenia spectrum disorder. J Psychiatr Res 2021;135:143-51. [PMID: 33486162 DOI: 10.1016/j.jpsychires.2021.01.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kulaksizoglu S, Kulaksizoglu B. The relationship between metabolic syndrome, BDNF, and vitamin D in patients with schizophrenia. Neurochem J 2017;11:104-11. [DOI: 10.1134/s1819712417010056] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
14 Kim EY, Kim SH, Lee HJ, Kim B, Kim YS, Ahn YM. Sex-specific association between the albumin D-element binding protein gene and metabolic syndrome in patients with bipolar disorder and schizophrenia. Psychiatry Res 2016;240:47-52. [PMID: 27084990 DOI: 10.1016/j.psychres.2016.03.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Borovcanin MM, Vesic K, Jovanovic M, Mijailovic NR. Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview. World J Diabetes 2021; 12(10): 1731-1739 [PMID: 34754374 DOI: 10.4239/wjd.v12.i10.1731] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Wu C, Chiang M, Natarajan R, Fusaro-davis M, Cimpeanu C, Liu M, Harrington A, Fan X. Pilot lifestyle education intervention for patients with severe mental illness during the inpatient stay. Asian Journal of Psychiatry 2019;40:15-7. [DOI: 10.1016/j.ajp.2019.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Krefft M, Frydecka D, Śmigiel R, Misiak B. Metabolic Parameters in Patients with Prader-Willi Syndrome and DiGeorge Syndrome with Respect to Psychopathological Manifestation. Neuropsychiatr Dis Treat 2020;16:457-63. [PMID: 32103966 DOI: 10.2147/NDT.S236034] [Reference Citation Analysis]
18 Boozalis T, Devaraj S, Okusaga OO. Correlations between Body Mass Index, Plasma High-Sensitivity C-Reactive Protein and Lipids in Patients with Schizophrenia. Psychiatr Q 2019;90:101-10. [PMID: 30315442 DOI: 10.1007/s11126-018-9606-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Kucera J, Horska K, Hruska P, Kuruczova D, Micale V, Ruda-Kucerova J, Bienertova-Vasku J. Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue. Prog Neuropsychopharmacol Biol Psychiatry 2021;108:110165. [PMID: 33152383 DOI: 10.1016/j.pnpbp.2020.110165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ustohal L, Mayerova M, Horska K, Obdrzalkova M, Crhova H, Prikrylova Kucerova H, Ceskova E, Kasparek T. Hemodynamic and white blood cells parameters in patients with first-episode psychosis: a pilot longitudinal study. Int J Psychiatry Clin Pract 2021;:1-4. [PMID: 34375167 DOI: 10.1080/13651501.2021.1962357] [Reference Citation Analysis]
21 Jianguo L, Xueyang J, Cui W, Changxin W, Xuemei Q. Altered gut metabolome contributes to depression-like behaviors in rats exposed to chronic unpredictable mild stress. Transl Psychiatry 2019;9:40. [PMID: 30696813 DOI: 10.1038/s41398-019-0391-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 11.7] [Reference Citation Analysis]
22 Raue S, Wedekind D, Wiltfang J, Schmidt U. The Role of Proopiomelanocortin and α-Melanocyte-Stimulating Hormone in the Metabolic Syndrome in Psychiatric Disorders: A Narrative Mini-Review. Front Psychiatry 2019;10:834. [PMID: 31798479 DOI: 10.3389/fpsyt.2019.00834] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
23 Horska K, Ruda-Kucerova J, Drazanova E, Karpisek M, Demlova R, Kasparek T, Kotolova H. Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats. Neuropharmacology 2017;123:148-58. [PMID: 28595931 DOI: 10.1016/j.neuropharm.2017.06.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
24 Schiavone S, Camerino GM, Mhillaj E, Zotti M, Colaianna M, De Giorgi A, Trotta A, Cantatore FP, Conte E, Bove M, Tucci P, Morgese MG, Trabace L. Visceral Fat Dysfunctions in the Rat Social Isolation Model of Psychosis. Front Pharmacol 2017;8:787. [PMID: 29167640 DOI: 10.3389/fphar.2017.00787] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
25 Horska K, Kotolova H, Karpisek M, Babinska Z, Hammer T, Prochazka J, Stark T, Micale V, Ruda-Kucerova J. Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation. Toxicol Appl Pharmacol 2020;406:115214. [PMID: 32866524 DOI: 10.1016/j.taap.2020.115214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
26 Peng HL, Liu LN, Liu DL, Tan YY. Depression and non-alcoholic fatty liver disease: Association and potential mechanisms. Shijie Huaren Xiaohua Zazhi 2022; 30(7): 295-302 [DOI: 10.11569/wcjd.v30.i7.295] [Reference Citation Analysis]
27 Shea S, Lionis C, Kite C, Atkinson L, Chaggar SS, Randeva HS, Kyrou I. Non-Alcoholic Fatty Liver Disease (NAFLD) and Potential Links to Depression, Anxiety, and Chronic Stress. Biomedicines 2021;9:1697. [PMID: 34829926 DOI: 10.3390/biomedicines9111697] [Reference Citation Analysis]
28 Fond G, Godin O, Brunel L, Aouizerate B, Berna F, Bulzacka E, Capdevielle D, Chereau I, Dorey JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Le Strat Y, Micoulaud-Franchi JA, Misdrahi D, Rey R, Richieri R, Passerieux C, Schandrin A, Schürhoff F, Tronche AM, Urbach M, Vidalhet P, Llorca PM, Leboyer M; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group. Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set. J Affect Disord 2016;191:209-15. [PMID: 26674214 DOI: 10.1016/j.jad.2015.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
29 Boiko AS, Mednova IA, Kornetova EG, Semke AV, Bokhan NA, Loonen AJM, Ivanova SA. Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. Heliyon 2019;5:e02033. [PMID: 31317083 DOI: 10.1016/j.heliyon.2019.e02033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]